Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retrospective, Multicenter, Observational Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients

NCT04979988 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04979988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04979988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retrospective, Multicenter, Observational Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
August 2, 2021
Completion date
December 9, 2021
Enrollment
51 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

alk-positive non-small-cell lung cancer